Norplant indemnity offer from Wyeth-Ayerst does not conform to AMA policy adopted in 1992.
WYETH-AYERST NORPLANT INDEMNITY OFFER DOES NOT CONFORM WITH AMA ethical positions as set forth in a 1992 statement by an American Medical Association council. The association's Council on Ethical and Judicial Affairs said in June 1992 that offers of indemnity to physicians "constitute unacceptable gifts" ("The Pink Sheet" June 22, 1992, T&G-6). The council based its position on the assessment that an indemnity program adds a feature beyond patient need or medical considerations to the choice of products. The AMA group maintained that a "third party's offer to indemnify a physician for lawsuits arising from the physician's prescription or use of the third party's drug, device or other product, introduces inappropriate factors into medical decision making."
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth